Apolipoprotein Testing Market Report 2024

This Apolipoprotein Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The apolipoprotein testing market size has grown strongly in recent years. It will grow from $2.78 billion in 2023 to $2.93 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to a heightened emphasis on preventive healthcare, the outsourcing of diagnostic tests, new regulatory approvals and guidelines, an increasing geriatric population, and greater investment in clinical trials.

The apolipoprotein testing market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth in the forecast period can be attributed to the expansion of healthcare infrastructure, the development of new testing panels, the increasing prevalence of cardiovascular diseases, a deeper understanding of obesity-related disorders, and the rise of precision nutrition. Key trends during this period include advancements in bioinformatics tools, progress in gene editing technologies, improvements in sample handling and storage, integration of molecular diagnostics with telemedicine, and incorporation with digital health platforms.

The growing incidence of cardiovascular diseases is anticipated to drive the expansion of the apolipoprotein testing market in the future. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, leading to conditions such as heart attacks, strokes, and peripheral vascular disease. The rising prevalence of these disorders is linked to factors such as unhealthy diets, increasing obesity rates, and aging populations. Apolipoproteins, including ApoA-I and ApoB, play a key role in lipid transport within the blood. Testing their levels is important for evaluating cardiovascular disease risk and customizing lipid-lowering treatments. For example, a report from the American Heart Association in January 2024 noted that cardiovascular diseases led to 931,578 deaths in the US in 2021. Additionally, a report from January 2023 indicated 928,741 deaths in 2020 due to cardiovascular diseases. This growing prevalence of cardiovascular conditions is fueling the demand for apolipoprotein testing.

Leading companies in the apolipoprotein testing market are developing advanced heart health plans to offer more comprehensive evaluations and personalized recommendations for managing cholesterol and reducing cardiovascular risk. Enhanced heart health plans are upgraded wellness programs that provide detailed assessments and tailored advice to improve cardiovascular health. For instance, in January 2023, InsideTracker, a US-based personal health analysis company, launched its Ultimate Plan, which includes Apolipoprotein B (ApoB) measurement. ApoB is a key indicator of heart health, and elevated levels are linked to higher risks of atherosclerosis and heart disease. This plan offers users detailed insights into their ApoB levels compared to standard ranges and provides personalized lifestyle recommendations based on research by InsideTracker's science team.

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics company, acquired Abcam Limited for an undisclosed amount. This acquisition allows Danaher to leverage Abcam's advanced technologies and strong market presence to enhance its growth in the life sciences sector. The deal is expected to improve disease mapping and accelerate drug discovery. Abcam Limited, based in the UK, is a biotechnology company that offers an Apolipoprotein AI (APOA1) human in vitro ELISA kit.

Major companies operating in the apolipoprotein testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Mayo Clinic Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Bio-Rad Laboratories Inc., Randox Laboratories Ltd., R&D Systems Inc., Elabscience Bionovation Inc., Sekisui Diagnostics LLC, RayBiotech Inc., Mabtech AB, Bioss Inc., Aviva Systems Biology Corporation, Abnova Corporation, DiaSys Diagnostic Systems GmbH, Biocompare Inc., Enzo Life Sciences Inc., Eagle Biosciences Inc., CLOUD-CLONE CORP., ELK Biotechnology CO. Ltd., LifeSpan BioSciences Inc.

North America was the largest region in the apolipoprotein testing market in 2023. The regions covered in the apolipoprotein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the apolipoprotein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Apolipoprotein testing involves measuring specific apolipoproteins in the blood to evaluate cardiovascular risk and lipid metabolism. This testing helps assess an individual's risk for cardiovascular diseases by analyzing proteins involved in lipid metabolism.

The main apolipoproteins measured are apolipoprotein A-I, apolipoprotein B, and apolipoprotein E. Apolipoprotein A-I is crucial for lipid metabolism, predominantly found in high-density lipoprotein (HDL), and aids in removing excess cholesterol from the blood, thereby reducing the risk of heart disease. Various technologies, including immunoassays and polymerase chain reaction (PCR), are used for apolipoprotein testing. Applications of this testing include cardiovascular disease risk assessment, genetic testing, and more. It is utilized by hospitals and clinics, diagnostic laboratories, and research and academic institutions.

The apolipoprotein testing market research report is one of a series of new reports that provides apolipoprotein testing market statistics, including the apolipoprotein testing industry global market size, regional shares, competitors with the apolipoprotein testing market share, detailed Apolipoprotein testing market segments, market trends, and opportunities, and any further data you may need to thrive in the apolipoprotein testing industry. These apolipoprotein testing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The apolipoprotein testing market consists of revenues earned by entities by providing services such as monitoring lipid disorders, evaluating treatment effectiveness, and early detection of metabolic syndrome. The market value includes the value of related goods sold by the service provider or included within the service offering. The apolipoprotein testing market also includes sales of spectrophotometers, ELISA plate readers, and centrifuges. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.